Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

The U.S. FDA has granted orphan drug designation for Eli Lilly's olomorasib for treatment of KRAS G12C-mutant non-small cell ...

Despite a robust cash position, Revolution Medicines' high burn rate and lofty valuation increase risk and sensitivity to ...

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors Business Wire Tue, Jun 24, 2025, 4 ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

Researchers have identified a mutation in a common oncogene that may play an important role in colon cancer. Their findings ...

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces the development of novel ...

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS- ...

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors Provided by Business Wire Jun 24 ...